Affordable Access

[Target therapy for CML--applying maxizyme].

Authors
  • Tani, K
Type
Published Article
Journal
Nihon rinsho. Japanese journal of clinical medicine
Publication Date
Dec 01, 2001
Volume
59
Issue
12
Pages
2439–2444
Identifiers
PMID: 11766353
Source
Medline
License
Unknown

Abstract

Hammerhead type ribozyme, which have been frequently used for the purpose of specifically cleaving RNA at the GUC triplets in the experimental setting, can not be generally applicable for the gene therapy of leukemia with gene translocation. This is because the translocated sequence does not necessarily have the GUC triplets at the site of translocation. The introduction of new strategy which can specifically digest the chimera gene is considered to open new leukemia therapy with gene translocation. Maxizyme, a newly developed heterodimeric shortened ribozymes, can theoretically digest any types of chimeric genes at the site of translocation. In this review, our interesting results suggested the possible application of this maxizyme system for the treatment of chronic myelogenous leukemia with bcr/abl gene translocation.

Report this publication

Statistics

Seen <100 times